Linnaeus Therapeutics, Inc. announced the issuance of EP patent 3823617 by the European Patent Office (EPO) covering the pharmaceutical composition of matter for their lead compound, LNS8801. LNS8801 modulates G protein-coupled estrogen receptor activity, and has the potential to offer therapeutic benefits for diseases and conditions mediated through these receptors.
Linnaeus is a Penn lincensee and spinout that participated in the PCI Ventures UPstart program and was co-founded by Todd Ridky, MD, PhD, Associate Professor of Dermatology at Penn Medicine, and Chris Natale, PhD, collaborating scientist in the Ridky Lab and VP of Research, Linnaeus. PATENT INFO
Linnaeus is currently conducting a phase 1/2 study for advanced cancer treatment and based on promising results from this study, it plans to initiate a pivotal trial in patients with metastatic cutaneous melanoma who have had confirmed progression on immune checkpoint inhibitors. Read more about the company here.